https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / BioDrugs 2005;19(5):289-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / BioDrugs 2005;19(5):289-972005-01-01 00:00:002019-02-15 09:25:42Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Expert Rev Vaccines 2004 Apr;3(2):163-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Expert Rev Vaccines 2004 Apr;3(2):163-702004-04-01 00:00:002004-04-01 00:00:00The role of idiotype vaccines in the treatment of human B-cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Leuk. Lymphoma 2003 Dec;44(12):2031-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Leuk. Lymphoma 2003 Dec;44(12):2031-82003-12-01 00:00:002019-02-15 08:51:25Dendritic cell-based immunotherapy in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-06-01 / Int. J. Hematol. 2003 Jun;77(5):444-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-06-01 / Int. J. Hematol. 2003 Jun;77(5):444-552003-06-01 00:00:002019-02-15 09:25:48Immunotherapy for lymphomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-04-01 / Haematologica 2002 Apr;87(4):400-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-04-01 / Haematologica 2002 Apr;87(4):400-72002-04-01 00:00:002019-02-15 09:25:49Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-02-22 / J. Biol. Chem. 2002 May;277(21):18986-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-02-22 / J. Biol. Chem. 2002 May;277(21):18986-932002-02-22 00:00:002002-02-22 00:00:00Enhancement of hyperthermia-induced apoptosis by local anesthetics on human histiocytic lymphoma U937 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2001-01-01 / Cancer Invest. 2001;19(8):791-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2001-01-01 / Cancer Invest. 2001;19(8):791-82001-01-01 00:00:002001-01-01 00:00:00Effect of hyperthermia on AKR lymphoma variants differing in degree of malignancy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1999-11-01 / Int J Hyperthermia 1999 Nov-Dec;15(6):475-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1999-11-01 / Int J Hyperthermia 1999 Nov-Dec;15(6):475-861999-11-01 00:00:001999-11-01 00:00:00Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
1996-01-01 / Int J Hyperthermia 1996 Jan-Feb;12(1):3-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
1996-01-01 / Int J Hyperthermia 1996 Jan-Feb;12(1):3-201996-01-01 00:00:001996-01-01 00:00:00Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology
